C12N 2310/3125
Methylphosphonates
C12N2310/3125 (Methylphosphonates) appears on 239 US grants and 271 published applications in this corpus.
Search patents in C12N- Granted patents
- 239
- Published applications
- 271
- Assignees
- 118
- Inventors
- 502
- Latest grant
- 7 Jul 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1992 | 2 | 0 |
| 1993 | 3 | 0 |
| 1994 | 2 | 0 |
| 1995 | 3 | 0 |
| 1996 | 12 | 0 |
| 1997 | 20 | 0 |
| 1998 | 15 | 0 |
| 1999 | 11 | 0 |
| 2000 | 8 | 0 |
| 2001 | 11 | 2 |
| 2002 | 12 | 4 |
| 2003 | 8 | 14 |
| 2004 | 6 | 12 |
| 2005 | 3 | 7 |
| 2006 | 7 | 6 |
| 2007 | 2 | 7 |
| 2008 | 2 | 5 |
| 2009 | 3 | 6 |
| 2010 | 7 | 5 |
| 2011 | 6 | 2 |
| 2012 | 7 | 5 |
| 2013 | 3 | 3 |
| 2014 | 3 | 5 |
| 2015 | 6 | 10 |
| 2016 | 6 | 6 |
| 2017 | 7 | 11 |
| 2018 | 4 | 6 |
| 2019 | 2 | 12 |
| 2020 | 10 | 11 |
| 2021 | 9 | 10 |
| 2022 | 4 | 17 |
| 2023 | 6 | 23 |
| 2024 | 9 | 36 |
| 2025 | 13 | 26 |
| 2026 | 7 | 20 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Compositions and methods for modulating SCAP activity7 Jul 2026US 12,674,169 B2Dicerna Pharmaceuticals, Inc.
- Complement Factor B-modulating compositions and methods of use thereof7 Apr 2026US 12,595,477 B2ADARx Pharmaceuticals, Inc.
- Methods and compositions for neuroprotection7 Apr 2026US 12,595,481 B2Disarm Therapeutics, Inc.
- Complement component C5 iRNA compositions and methods of use thereof31 Mar 2026US 12,590,305 B2Alnylam Pharmaceuticals, Inc.
- RNA-based adjuvant to enhance the immune response to vaccines and therapeutics24 Mar 2026US 12,582,711 B2Immunesure LLC
- Treatment of gpam related diseases and disorders8 Oct 2026US 2026/0308594 A1Empirico Inc.
- Nucleic Acid Antisense Oligomer Readthrough of Nonsense Codons1 Oct 2026US 2026/0297572 A1University of Massachusetts
- Compositions and methods for silencing ugt1a1 gene expression1 Oct 2026US 2026/0297589 A1Alnylam Pharmaceuticals, Inc.
- Antisense RNA (asRNA) Technology and Use Thereof24 Sep 2026US 2026/0286353 A11Globe Health Institute LLC
- Antisense oligonucleotides for the treatment of neurological disorders17 Sep 2026US 2026/0275339 A1Eli Lilly and Company
Most cited
By later US patents
- N-2 substituted purines806US 5,459,255 AIsis Pharmaceuticals, Inc. · 1995
- Sugar modified oligonucleotides that detect and modulate gene expression641US 5,670,633 AIsis Pharmaceuticals, Inc. · 1997
- Oligonucleotides having phosphorothioate linkages of high chiral purity626US 5,587,361 AIsis Pharmaceuticals, Inc. · 1996
- Oligonucleotides containing N-2 substituted purines621US 5,587,469 AIsis Pharmaceuticals, Inc. · 1996
- Substituted purines and oligonucleotide cross-linking603US 5,681,941 AIsis Pharmaceuticals, Inc. · 1997